Vimy Pharma raises US$10.6M as it moves to go public via reverse takeover
What's the deal? Vimy Pharmaceuticals has closed a brokered private placement for aggregate gross proceeds of US$10.7M, issuing 4,846,354 subscription receipts at $3.00 each. The raise came in two tranches, the second of which added US$1.82M on October 22, 2026.
Who's involved? Beacon SecuritiesDealroom has a profile for this one. Try Dealroom → acted as lead agent and sole bookrunner, leading a syndicate that included Haywood SecuritiesDealroom has a profile for this one. Try Dealroom →, Leede Financial, and Research CapitalDealroom has a profile for this one. Try Dealroom →.
Why now? The placement is tied to a planned go-public transaction. Vimy PharmaDealroom has a profile for this one. Try Dealroom → and Harmony Acquisitions Corp. (TSXV: MONY.P) have agreed to a business combination that will constitute a reverse takeover of Harmony.
What's the endgame? Shareholders have cleared the path. Harmony's shareholders approved all resolutions on October 19, 2026, and Vimy Pharma's shareholders subsequently approved the transaction and related matters.
How it works: Each subscription receipt converts into one Vimy Pharma common share once escrow release conditions are met, with funds then released to the company. If those conditions are not satisfied within 120 days of the first tranche's close — extendable by up to 30 days — the receipts are cancelled and funds returned to subscribers with interest.
The signal: The financing and shareholder votes move Vimy Pharma closer to a public listing through a reverse takeover, a route that lets private companies reach the market without a traditional initial public offering.
Read more: wallstreet-online.de
Image credit: thetaxhaven
